Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart

Life Sciences

Volumn 79, Issue 4, 2006, Pages 356-364

  Lourenco, Celia M ^a   Kenk, Miran ^a,b,c   Beanlands, Rob S ^b   DaSilva, Jean N ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Brain and heart imaging; cAMP; PDE4; Positron emission tomography; Rolipram; Signal transduction

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CARBON 11; COCAINE; CYCLIC AMP; DESIPRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; HISTAMINE; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM C 11; SEROTONIN; SERTRALINE; THIOPERAMIDE; TRACER; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG RETENTION; DRUG UPTAKE; ENZYME ACTIVITY; HEART; LUNG; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEART; HISTAMINE; LUNG; MALE; MYOCARDIUM; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPSES; TRANYLCYPROMINE;

EID: 33744546885     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.010     Document Type: Article

References (54)

1. 2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacology & Toxicology 62 (1988) 121-130
2. 4B receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn-Schmiedeberg's Archives of Pharmacology 363 2 (2001) 146-160
3. 4 mRNA in heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology 370 3 (2004) 157-166
4. Budygin E.A., Kilpatrick M.R., Gainetdinov R.R., and Wightman R.M. Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry. Neuroscience Letters 281 1 (2000) 9-12
5. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Progress in Nucleic Acid Research and Molecular Biology 63 (1999) 1-38
6. Cowburn R.F., O'Neill C., Ravid R., Alafuzoff I., Winblad B., and Fowler C.J. Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimer's disease. Journal of Neurochemistry 58 (1992) 1409-1419
7. Dasi F.J., Ortiz J.L., Cortijo J., and Morcillo E.J. Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. Inflammation Research 49 11 (2000) 600-609
8. 11C]rolipram. Journal of Labelled Compounds & Radiopharmaceuticals 44 5 (2001) 373-384
9. 11C]rolipram and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 29 12 (2002) 1680-1683
10. 2 receptor stimulation and cAMP increase. Medical Science Monitor 9 6 (2003) BR252-BR259
11. Dinter H., Onuffer J., Faulds D., and Perez H.D. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. Journal of Molecular Medicine 75 (1997) 95-102
12. Engels P., Fichtel K., and Lübbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Letters 350 (1994) 291-295
13. Feldman A.M. Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation 87 5 Suppl. (1993) IV27-IV34
14. Fujita M., and Innis R.B. Nuclear psychiatry: specialty for the twenty-first century?. European Journal of Nuclear Medicine 27 1 Suppl. (2000) S39-S42
15. Garcia-Sevilla J.A., and Zubieta J.K. Activation and desensitization of presynaptic alpha 2-adrenoceptors after inhibition of neuronal uptake by antidepressant drugs in the rat vas deferens. British Journal of Pharmacology 89 4 (1986) 673-683
16. Giralt M.T., and Garcia-Sevilla J.A. Acute and long-term regulation of brain alpha 2-adrenoceptors after manipulation of noradrenergic transmission in the rat. European Journal of Pharmacology 164 3 (1989) 455-466
17. 3 autoreceptors modulate histamine synthesis through cAMP pathway. Molecular Pharmacology 61 1 (2002) 239-245
18. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson W.R.J., Kirby D.S., and Weiner E.S. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. The Journal of Investigative Dermatology 107 (1996) 51-56
19. 1 receptor modulation in the living brain: a PET study in conscious monkeys. Synapse 44 3 (2002) 139-145
20. Houslay M.D., Sullivan M., and Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Advances in Pharmacology 44 (1998) 225-342
21. Johnson R.W., Reisine T., Spotnitz S., Wiech N., Ursillo R., and Yamamura H.I. Effects of desipramine and yohimbine on alpha 2- and beta-adrenoreceptor sensitivity. European Journal of Pharmacology 67 1 (1980) 123-127
22. Kajimoto K., Hagiwara N., Kasanuki H., and Hosoda S. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. British Journal of Pharmacology 121 (1997) 1549-1556
23. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
24. Koch W.J., Lefkowitz R.J., and Rockman H.A. Functional consequences of altering myocardial adrenergic receptor signaling. Annual Review of Physiology 62 (2000) 237-260
25. Laliberte F., Han Y., Govindarajan A., Giroux A., Liu S., Bobechko B., Lario P., Bartlett A., Gorseth E., Gresser M., and Huang Z. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39 21 (2000) 6449-6458
26. 2 receptors in the U937 cell line. Biochemical Pharmacology 60 2 (2000) 159-166
27. 3-receptors: a new frontier in myocardial ischemia. The Journal of Pharmacology and Experiemental Therapeutics 292 3 (2000) 825-830
28. 11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nuclear Medicine and Biology 28 4 (2001) 347-358
29. Madelian V., and La Vigne E. Rapid Regulation of a Cyclic AMP-Specific Phosphodiesterase (PDE IV) by Forskolin and Isoproterenol in LRM55 Astroglial Cells. Biochemical Pharmacology 51 (1996) 1739-1747
30. Makhay M.M., Houslay M.D., and O'Donnell J.M. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology (Berlin) 158 3 (2001) 297-304
31. Malagie I., Trillat A.C., Jacquot C., and Gardier A.M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. European Journal of Pharmacology 286 2 (1995) 213-217
32. Manning C.D., McLaughlin M.M., Livi G.P., Cieslinski L.B., Torphy T.J., and Barnette M.S. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4 A and 4 B. The Journal of Pharmacology and Experimental Therapeutics 276 2 (1996) 810-818
33. Miro X., Perez-Torres S., Artigas F., Puigdomenech P., Palacios J.M., and Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 43 7 (2002) 1148-1157
34. Mori T., Baba J., Ichimaru Y., and Suzuki T. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Japanese Journal of Pharmacology 83 2 (2000) 113-118
35. Müller B., Lugnier C., and Stoclet J.-C. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. Journal of Cardiovascular Pharmacology 16 (1990) 796-803
36. O'Connolly M., Dierdorf D., Greb W.H., Mayer M.-E.R., and Wolf D. Efficacy of denbufylline in patients with multi-infarct dementia. Drug Development Research 14 (1988) 195-198
37. 3-agonist (R)-alpha-methylhistamine and the antagonist thioperamide on histamine metabolism in the mouse and rat brain. Journal of Neurochemistry 52 5 (1989) 1388-1392
38. Polli J.W., and Kincaid R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. The Journal of Neuroscience 14 3 Pt 1 (1994) 1251-1261
39. 6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochemical and Biophysical Research Communications 193 1 (1993) 268-276
40. 7) activating cAMP formation. Proceedings of the National Academy of Sciences of the United States of America 90 18 (1993) 8547-8551
41. Saletu B., Anderer P., Fischhof P.K., Lorenz H., Barousch R., and Böhmer F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biological Psychiatry 32 (1992) 668-681
42. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. European Journal of Pharmacology 127 (1986) 105-115
43. Sette C., Iona S., and Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. The Journal of Biological Chemistry 269 12 (1994) 9245-9252
44. Sturton G., and Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 121 5 Suppl. (2002) 192S-196S
45. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4 A and 4 B isoforms. The Journal of Neuroscience 19 (1999) 610-618
46. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. American Journal of Respiratory and Critical Care Medicine 157 2 (1998) 351-370
47. Torres G.E., Chaput Y., and Andrade R. Cyclic AMP and protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in adult hippocampal neurons. Molecular Pharmacology 47 1 (1995) 191-197
48. Tsukada H., Harada N., Ohba H., Nishiyama S., and Kakiuchi T. Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain. Synapse 42 4 (2001) 258-265
49. Verghese M.W., McConnell R.T., Lenhard J.M., Hamacher L., and Jin S.-L.C. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Molecular Pharmacology 47 (1995) 1164-1171
50. Wachtel H. The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry 23 (1990) 27-32
51. Whalin M.E., Garrett Jr. R.L., Thompson W.J., and Strada S.J. Correlation of cell-free brain cyclic nucleotide phosphodiesterse activities to cyclic AMP decay in intact brain slices. Second Messengers and Phosphoproteins 12 5 & 6 (1989) 311-325
52. Xiang Y., Naro F., Zoudilova M., Jin S.L., Conti M., and Kobilka B. Phosphodiesterase 4 D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proceedings of the National Academy of Sciences of the United States of America 102 3 (2005) 909-914
53. Ye Y., Jackson K., and O'Donnell J.M. Effects of repeated antidepressant treatment of type 4 A phosphodiesterase (PDE4A) in rat brain. Journal of Neurochemistry 74 3 (2000) 1257-1262
54. Zahniser N.R., Larson G.A., and Gerhardt G.A. In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors. Journal of Pharmacology and Experimental Therapeutics 289 1 (1999) 266-277